Accès gratuit
Med Sci (Paris)
Volume 19, Numéro 8-9, Août-Septembre 2003
Page(s) 860 - 863
Section M/S Revues
Publié en ligne 15 août 2003
  1. Ørskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992; 35: 701–11. [Google Scholar]
  2. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretinvasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993; 133: 2861–70. [Google Scholar]
  3. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide I. Proc Natl Acad Sci USA 1992; 89: 8641–5. [Google Scholar]
  4. Weir GC, Mojsov S, Hendrick GK, Habener JF. Glucagonlike peptide 1 (7-37) actions on endocrine pancreas. Diabetes 1989; 38: 338–42. [Google Scholar]
  5. Ozaki N, Shibasaki T, Kashima Y, et al. cAMPGEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2000; 2: 805–11. [Google Scholar]
  6. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270–6. [Google Scholar]
  7. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto- Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002; 51: 1443–52. [Google Scholar]
  8. Stoffers DA, Kieffer TJ, Hussain MA, et al.Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49: 741–8. [Google Scholar]
  9. Ehses JA, Pelech SL, Pederson RA, McIntosh CHS. Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2- ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1- mediated pathway. J Biol Chem 2002; 277: 37088–97. [Google Scholar]
  10. Gomez E, Pritchard C, Herbert TP. cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate rafindependent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic β-cells. J Biol Chem 2002; 277 : 48146–51. [Google Scholar]
  11. Schjoldager BTG, Mortensen PE, Christiansen J, Ørskov C, Holst JJ. GLP-1 (glucagonlike peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci 1989; 3 : 703–8. [Google Scholar]
  12. Wettergren A, Vojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998; 275: G984–92. [Google Scholar]
  13. Turton MD, O’SHea D, Gunn I, et al. A role for glucagonlike peptide-1 in the central regulation of feeding. Nature 1996; 379: 69–72. [Google Scholar]
  14. Szayna M, Doyle ME, Betkey JA, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000; 141: 1936–41. [Google Scholar]
  15. Larsen PJ, Tang-Christansen M, Holst JJ, Ørskov C. Distribution of glucagonlike peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997; 77: 257–70. [Google Scholar]
  16. Burcelin R, Dolci W, Thorens B. Glucose sensing by the hepatoportal sensor is GLUT2-dependent. In vivo analysis in GLUT2-null mice. Diabetes 2000; 49: 1643–8. [Google Scholar]
  17. Burcelin R, DaCosta A, Drucker D, Thorens B. Glucose competence of the hepatoporal vein sensor requires the presence of an activated GLP-1 receptor. Diabetes 2001; 50: 1720–8. [Google Scholar]
  18. Scrocchi LA, Brown TJ, MacLusky N, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagonlike peptide-1 receptor gene. Nat Med 1996; 2: 1254–8. [Google Scholar]
  19. Miyawaki K, Yamada Y, Yano H, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 14843–7. [Google Scholar]
  20. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738–42. [Google Scholar]
  21. Rachman J, Gribble FM, Barrows BE, Levy JC, Buchanan KD, Turner RC. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7- 36) amide in patients with NIDDM. Diabetes 1996; 45: 1524–30. [Google Scholar]
  22. Rachman J, Barrows BA, Levy JC, Turner RC. Nearnormalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjets with NIDDM. Diabetologia 1997; 40: 205–11. [Google Scholar]
  23. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagonlike peptide 1 on glycaemic control, insulin sensitivity, and β cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824–30. [Google Scholar]
  24. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002; 18: 430–41. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.